House Bill 2101, also known as Senate Bill 2323, amends various provisions of the Tennessee Code Annotated related to the regulation of drugs, specifically focusing on the sale of products containing pseudoephedrine and ephedrine. Key changes include the requirement for pharmacies to implement an electronic sales tracking system by January 1, 2012, to monitor the sale of these products. The bill mandates that pharmacies electronically submit required information before completing sales and outlines the process for correcting data entry errors. Additionally, it establishes that pharmacies will not be held civilly liable for actions taken in compliance with the electronic tracking system, provided there is no negligence or misconduct.

The bill also updates the definitions and responsibilities associated with the electronic sales tracking system, including the requirement for manufacturers of ephedrine and pseudoephedrine products to pay monthly fees starting January 1, 2027. It modifies the language throughout the relevant sections to replace references to "NPLEx" with "electronic sales tracking system" and clarifies the role of the administrator of this system. Furthermore, the bill increases the maximum allowable purchase limit for these products from 43.2 grams to 61.2 grams. The act is set to take effect on July 1, 2026.

Statutes affected:
Introduced: 39-17-431(c)(4), 39-17-431, 39-17-431(d), 39-17-431(e), 39-17-431(i), 39-17-431(j)(1), 39-17-431(j)(2), 39-17-431(l), 39-17-431(o), 39-17-431(c)